Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for XEN1101 in Mental health, Major depressive disorder. The expected timing is based on the latest available company guidance and may change.
X-NOVA2/3 studies. Collab w/ Icahn School of Medicine. 5/3/22- trial initiated. 5/28/24- Presentation at ASCP '24. 2/27/25- Enrollment ongoing w/ X-NOVA3 initiation by mid-year. 11/03/25:- X-NOVA2 and X-NOVA3 Phase 3 MDD studies are underway and continuing to recruit patients. 02/26/26:- X-NOVA2 and X-NOVA3 MDD Ph3 trials enrolling; X-NOVA2 topline data expected in H1 2027. 05/07/26:- X-NOVA2 and X-NOVA3 Ph3 MDD trials continue enrolling; X-NOVA2 topline data remains expected in H1 2027. 08/06/26:- X-NOVA2 Phase 3 MDD topline data remains expected in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.